Noel Thomas Doheny

Noel Thomas Doheny

Chief Executive Officer at Epigenomics, Inc.

Health Technology
Commercial Services
Process Industries

Profile

Noel Thomas Doheny is currently the Chief Executive Officer at Epigenomics, Inc. He also holds director positions at Cernostics, Inc. and Integrated Nano-Technologies, Inc. Previously, he served as the Chief Executive Officer at OpGen, Inc., Senior Vice President at Affymetrix, Inc., President at BioStar, Inc., and Member-Management Board at Epigenomics AG.
He also held positions at QIAGEN Sciences, Inc., Ciba Corning Diagnostics Corp., and Gilford Instruments Laboratories, Inc. Doheny received his undergraduate degree from West Virginia University.

Noel Thomas Doheny active positions

CompaniesPositionStart
Chief Executive Officer 2011-06-12
Director/Board Member -
Director/Board Member -
All active positions of Noel Thomas Doheny

Former positions of Noel Thomas Doheny

CompaniesPositionEnd
EPIGENOMICS AG Corporate Officer/Principal 2016-05-29
Corporate Officer/Principal 2014-01-14
Gilford Instruments Laboratories, Inc. Corporate Officer/Principal -
Ciba Corning Diagnostics Corp. Corporate Officer/Principal -
BioStar, Inc. President -
See the detail of Noel Thomas Doheny's experience

Training of Noel Thomas Doheny

West Virginia University Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Noel Thomas Doheny's experience

Connections

16

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies2
OPGEN, INC.

Commercial Services

EPIGENOMICS AG

Health Technology

Private companies8

Process Industries

Health Technology

BioStar, Inc.

Health Technology

Ciba Corning Diagnostics Corp.

Commercial Services

Health Technology

Gilford Instruments Laboratories, Inc.

Health Technology

See company connections
  1. Stock Market
  2. Insiders
  3. Noel Thomas Doheny
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW